4.5 Article

Distribution of perfluorooctanesulfonate and perfluorooctanoate into human plasma lipoprotein fractions

期刊

TOXICOLOGY LETTERS
卷 210, 期 3, 页码 360-365

出版社

ELSEVIER IRELAND LTD
DOI: 10.1016/j.toxlet.2012.02.013

关键词

Perfluorooctanoate; Perfluorooctanesulfonate; Cholesterol; Lipoprotein; Fractionation

资金

  1. 3M Company

向作者/读者索取更多资源

Some cross-sectional epidemiological studies have reported positive associations of serum concentrations of non-high density lipoprotein cholesterol with serum perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA). However, the strength of the reported associations is inconsistent for exposure-response across three orders of magnitude of serum PFOS and/or PFOA concentrations. These positive associations are unexpected based on toxicological/mechanistic studies, suggesting that the associations may have a biological, rather than a causal, basis. This study tested the hypothesis that PFOS and PFOA distribute into serum lipoprotein fractions such that increases in serum lipoproteins would result in corresponding increases in serum concentrations of PFOS and PFOA. Based on observed binding of PFOS and PFOA to isolated beta-lipoproteins in physiological saline (96% and 40% bound, respectively) in preliminary experiments using ultrafiltration and LC-MS/MS methods, binding to human donor plasma lipoprotein fractions was investigated by two density gradient methods. The majority of PFOS and PFOA recovered masses were found in lipoprotein-depleted plasma. Plasma density gradient fractionation data suggested that maximally 9% of PFOS distributes to lipoprotein-containing fractions, yet only 1% or less of PFOA is so distributed. These data do not support a strong role for plasma lipoprotein fractions in explaining the inconsistent dose-response associations reported in cross-sectional epidemiological studies. (C) 2012 Elsevier Ireland Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Behavioral Sciences

No effects of PCSK9-inhibitor treatment on spatial learning, locomotor activity, and novel object recognition in mice

Frieder Schlunk, Paul Fischer, Hans M. G. Princen, Andre Rex, Vincent Prinz, Marco Foddis, Dieter Luetjohann, Ulrich Laufs, Matthias Endres

Summary: In this mouse study, treatment with anti-PCSK9 antibodies did not lead to differences in behavior or changes in cognition.

BEHAVIOURAL BRAIN RESEARCH (2021)

Article Pharmacology & Pharmacy

Effects of mineral oil administration on the pharmacokinetics, metabolism and pharmacodynamics of atorvastatin and pravastatin in mice and dogs

V. Sashi Gopaul, Elsbet J. Pieterman, Hans M. G. Princen, Linnea Bergenholm, Eva Lundborg, Anders Cavallin, Magnus J. Johansson, Glen Hawthorne, Anders Bjorkbom, Maria Hammarberg, XueQing Li, Annica Jarke, Jonathan Bright, Lena Svensson, Rasmus Jansson-Lofmark, Bertil Abrahamsson, Rahul Agrawal, Eva Hurt-Camejo

Summary: The results in mice and dogs indicate that mineral oil does not affect the pharmacokinetics of atorvastatin or pravastatin, but may cause low-grade inflammation with chronic oral administration, warranting further investigation.

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2021)

Article Orthopedics

Novel high-intensive cholesterol-lowering therapies do not ameliorate knee OA development in humanized dyslipidemic mice

Y. van Gemert, A. E. Kozijn, M. G. Pouwer, N. N. L. Kruisbergen, M. H. J. van den Bosch, A. B. Blom, E. J. Pieterman, H. Weinans, R. Stoop, H. M. G. Princen, P. L. E. M. van Lent

Summary: The study found that therapeutic cholesterol lowering did not reduce cartilage degradation progression in dyslipidemic mice, suggesting that inflammation is a key feature of the disease and therapeutic cholesterol-lowering strategies may still hold promise.

OSTEOARTHRITIS AND CARTILAGE (2021)

Article Multidisciplinary Sciences

Beneficial effects of elafibranor on NASH in E3L.CETP mice and differences between mice and men

Anita M. van den Hoek, Lars Verschuren, Martien P. M. Caspers, Nicole Worms, Aswin L. Menke, Hans M. G. Princen

Summary: The study investigated the response of Elafibranor in APOE*3Leiden.CETP mice, demonstrating its ability to significantly reduce steatosis and hepatic inflammation, and preclude progression of fibrosis. Comparison of disease pathways in the model and NASH patients showed substantial similarity, indicating potential usefulness of Elafibranor in treating human NASH, possibly in combination with other agents.

SCIENTIFIC REPORTS (2021)

Review Toxicology

Systemic PFOS and PFOA exposure and disturbed lipid homeostasis in humans: what do we know and what not?

Styliani S. Fragki, Hubert Dirven, Tony Fletcher, Bettina Grasl-Kraupp, Kristine Bjerve Gutzkow, Ron Hoogenboom, Sander Kersten, Birgitte Lindeman, Jochem Louisse, Ad Peijnenburg, Aldert H. Piersma, Hans M. G. Princen, Maria Uhl, Joost Westerhout, Marco J. Zeilmaker, Mirjam Luijten

Summary: The association between PFOS/PFOA and increased blood lipids in humans has been observed, while rodent studies show opposite effects, likely due to different exposure levels. Mechanistic research suggests that PFOS/PFOA activate the PPAR alpha pathway in human liver cells, but the involvement of other nuclear receptors is less clear. Future studies focusing on human-relevant test systems are needed to better understand the implications of PFOS/PFOA exposure on lipid homeostasis and human health.

CRITICAL REVIEWS IN TOXICOLOGY (2021)

Article Cardiac & Cardiovascular Systems

Common Variants Associated With OSMR Expression Contribute to Carotid Plaque Vulnerability, but Not to Cardiovascular Disease in Humans

Danielle van Keulen, Ian D. van Koeverden, Arjan Boltjes, Hans M. G. Princen, Alain J. van Gool, Gert J. de Borst, Folkert W. Asselbergs, Dennie Tempel, Gerard Pasterkamp, Sander W. van der Laan

Summary: The study found that a genetic variant (rs1316887) in the OSMR locus is associated with increased plaque vulnerability, but not with coronary calcification or cardiovascular disease risk. The precise biological mechanisms through which OSM signaling affects plaque morphology remain unclear.

FRONTIERS IN CARDIOVASCULAR MEDICINE (2021)

Article Pharmacology & Pharmacy

The tyrosine kinase inhibitor nilotinib targets the discoidin domain receptor DDR2 in calcific aortic valve stenosis

Miguel Carracedo, Sven-Christian Pawelzik, Gonzalo Artiach, Marianne G. Pouwer, Oscar Plunde, Peter Saliba-Gustafsson, Ewa Ehrenborg, Per Eriksson, Elsbet Pieterman, Leif Stenke, Hans M. G. Princen, Anders Franco-Cereceda, Magnus Back

Summary: This study found that nilotinib can promote aortic valve thickening and valvular interstitial cell calcification, while imatinib does not have this effect. The study also found differential tyrosine kinase expression between healthy and calcified valve tissue. These findings may have important implications for cardiovascular surveillance and personalized medicine in chronic myeloid leukaemia patients.

BRITISH JOURNAL OF PHARMACOLOGY (2022)

Article Biochemistry & Molecular Biology

A Novel, Orally Bioavailable, Small-Molecule Inhibitor of PCSK9 With Significant Cholesterol-Lowering Properties In Vivo

Alexandra K. Suchowerska, Geurt Stokman, James T. Palmer, Phillip A. Coghlan, Elsbet J. Pieterman, Nanda Keijzer, Gilles Lambert, Kevin Chemello, Ali K. Jaafar, Jasneet Parmar, Liping Yan, Yingtao Tong, Lin Mu, Hans M. G. Princen, James Bonnar, Benny J. Evison

Summary: This study reported the discovery of an orally bioavailable small-molecule inhibitor of PCSK9 called NYX-PCSK9i, which demonstrated significant cholesterol-lowering activity in hyperlipidemic APOE*3-Leiden.CETP mice. NYX-PCSK9i has the potential to be a new therapy for hypercholesterolemia and can enhance the lipid-lowering activities of statins.

JOURNAL OF LIPID RESEARCH (2022)

Article Orthopedics

IL-1β inhibition combined with cholesterol-lowering therapies decreases synovial lining thickness and spontaneous cartilage degeneration in a humanized dyslipidemia mouse model

Y. van Gemert, N. N. L. Kruisbergen, A. B. Blom, M. H. J. van den Bosch, P. M. van der Kraan, E. J. Pieterman, H. M. G. Princen, P. L. E. M. van Lent

Summary: Inhibition of IL-1 beta combined with cholesterol-lowering therapy can reduce synovial thickening and cartilage degeneration in mice, suggesting its potential benefits for patients with metabolic inflammation.

OSTEOARTHRITIS AND CARTILAGE (2023)

Article Biochemistry & Molecular Biology

Atorvastatin Attenuates Diet-Induced Non-Alcoholic Steatohepatitis in APOE*3-Leiden Mice by Reducing Hepatic Inflammation

Jose A. Inia, Geurt Stokman, Elsbet J. Pieterman, Martine C. Morrison, Aswin L. Menke, Lars Verschuren, Martien P. M. Caspers, Martin Giera, J. Wouter Jukema, Anita M. van den Hoek, Hans M. G. Princen

Summary: Patients with metabolic syndrome are often prescribed statins to prevent cardiovascular disease, but their effects on NASH are lacking. This study found that atorvastatin can significantly reduce hepatic steatosis, inflammation, and fibrosis, as well as prevent cholesterol crystal formation and NLRP3 inflammasome activation.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Biochemistry & Molecular Biology

Semaglutide Has Beneficial Effects on Non-Alcoholic Steatohepatitis in Ldlr-/-.Leiden Mice

Jose A. Inia, Geurt Stokman, Martine C. Morrison, Nicole Worms, Lars Verschuren, Martien P. M. Caspers, Aswin L. Menke, Louis Petitjean, Li Chen, Mathieu Petitjean, J. Wouter Jukema, Hans M. G. Princen, Anita M. van den Hoek

Summary: Semaglutide, a glucagon-like peptide-1 receptor agonist, has been approved for the treatment of obesity and shows potential for the treatment of non-alcoholic steatohepatitis (NASH). It significantly reduces hepatic steatosis and inflammation, but has limited effects on fibrosis. Combining Semaglutide with other NASH agents may be necessary for the reversal of advanced fibrosis.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Orthopedics

Intensive cholesterol-lowering treatment reduces synovial inflammation during early collagenase-induced osteoarthritis, but not pathology at end-stage disease in female dyslipidemic E3L.CETP mice

Y. van Gemert, A. B. Blom, I. Di Ceglie, B. Walgreen, M. Helsen, A. Sloetjes, T. Vogl, J. Roth, N. N. L. Kruisbergen, E. J. Pieterman, H. M. G. Princen, P. M. van der Kraan, P. L. E. M. van Lent, M. H. J. van den Bosch

Summary: The study investigated the effects of intensive cholesterol-lowering treatment on joint inflammation and pathology in a collagenase-induced osteoarthritis model. While the treatment reduced inflammation, it did not significantly impact end-stage disease.

OSTEOARTHRITIS AND CARTILAGE (2023)

Meeting Abstract Cardiac & Cardiovascular Systems

EFFICACY OF A NOVEL PCSK9 INHIBITORY PEPTIDE ALONE AND IN COMBINATION WITH AN ANTI-ANGPTL3 MONOCLONAL ANTIBODY IN A MOUSE MODEL OF ATHEROSCLEROSIS

B. Rolin, H. M. G. Princen, A. M. Van den Hoek, G. Rakipovski, J. F. Lau, P. W. Garibay, C. K. Mogensen

ATHEROSCLEROSIS (2022)

Meeting Abstract Endocrinology & Metabolism

Effects of PCSK9 inhibition or deletion on intracerebral hemorrhage lesion volume in mice

Paul Fischer, Frieder Schlunk, Hans M. G. Princen, Andre Rex, Vincent Prinz, Marco Foddis, Dieter Lutjohann, Ulrich Laufs, Matthias Endres

JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2022)

Meeting Abstract Orthopedics

IL-1β INHIBITION COMBINED WITH CHOLESTEROL-LOWERING THERAPIES DECREASES SYNOVIAL LINING THICKNESS AND SPONTANEOUS CARTILAGE DEGENERATION IN A HUMANIZED DYSLIPIDEMIA MOUSE MODEL

Y. van Gemert, N. N. Kruisbergen, M. H. van den Bosch, A. B. Blom, P. M. van der Kraan, E. J. Pieterman, H. M. Princen, P. L. van Lent

OSTEOARTHRITIS AND CARTILAGE (2022)

暂无数据